About This Project
Radiation damages DNA and contributes to aging, cancer, and other diseases. Deinococcus radiodurans survives radiation doses thousands of times higher than humans thanks in part to PprI, a protein that activates DNA repair. Remarkably, PprI may also protect human cells, but how it works remains unknown. We will test PprI in human cells to uncover its mechanism and identify the proteins it interacts with, laying the groundwork for new radiation-protective therapies.
Ask the Scientists
Join The DiscussionWhat is the context of this research?
Every day, human cells experience DNA damage from radiation, oxidative stress, aging, and disease. Although our cells possess sophisticated DNA repair pathways, these protective mechanisms are often insufficient after severe injury, contributing to tissue damage and disease.
One of the most radiation-resistant organisms ever discovered, Deinococcus radiodurans, survives by activating a coordinated stress response through a protein called PprI (also known as IrrE).
Previous studies have shown that PprI can also reduce radiation damage in mammalian cells, even though humans do not possess a known PprI pathway. How PprI produces this protective effect in human cells remains unknown.
This project will determine whether PprI enhances recovery from DNA damage in human cells and whether its protease activity is required for this effect.
What is the significance of this project?
If PprI activates endogenous repair pathways in mammalian cells, it could reveal a previously unrecognized mechanism for enhancing cellular resilience following DNA damage. Rather than replacing damaged cells or permanently altering the genome, this approach seeks to understand whether existing repair systems can be temporarily strengthened during periods of acute stress. Insights from this work could inform future strategies for protecting healthy tissues during radiation therapy, improving recovery after ischemic injury, enhancing organ preservation, and reducing cellular damage associated with disease. This project is designed as a proof-of-concept study to generate the first mechanistic evidence needed to determine whether PprI represents a promising lead for future therapeutic development or a gateway to discovering new regulators of human cellular repair.
What are the goals of the project?
The primary goal of this project is to determine whether the bacterial stress-response protein PprI enhances recovery from radiation-induced DNA damage in human cells and whether its protease activity is required for this effect. We will compare two PprI variants—wild-type and a catalytically inactive (protease-dead) mutant—alongside an empty-vector control in primary human endothelial cells and HEK293T cells for independent validation. Cell survival will be assessed following 0, 2, 4, and 6 Gy radiation. Mechanistic studies will evaluate γH2AX foci, RAD51 foci, and Annexin V staining, with all experiments performed in three independent biological replicates. Together, these studies will determine whether PprI provides reproducible radioprotection and define whether its protease activity is required to promote DNA repair in human cells, providing a strong foundation for future mechanistic studies.
Budget
This budget supports a proof-of-concept study investigating whether the bacterial stress-response protein PprI enhances recovery from DNA damage in human cells. All experiments will be performed by a qualified contract research organization (CRO). Budget estimates are based on CRO quotations and include materials, reagents, laboratory services, scientific personnel, specialized instrumentation (irradiators and fluorescence imaging systems), and data analysis. DNA construct costs cover gene synthesis, cloning, plasmid preparation, and sequence verification. Cell culture costs include media, serum, transfection reagents, and consumables. Radiation-study costs cover irradiation and cell-survival assays. DNA repair assay costs include γH2AX, RAD51, and Annexin V reagents and analysis. The protease-dead comparison includes mutant validation and experimental controls. The remaining budget supports CRO data analysis, technical reporting, and Experiment.com platform fees.
Endorsed by
Project Timeline
From funding, DNA constructs will be generated and validated before initiating mammalian cell studies. Human cells expressing wild-type or protease-deficient PprI will be evaluated following controlled radiation exposure using established assays of DNA damage and cellular recovery. Results will be analyzed, validated, and shared with supporters in a final technical report. If the findings are promising, they will provide the foundation for future mechanistic studies and therapeutic development.
Aug 10, 2026
Project Launched
Oct 30, 2026
Experimental design finalized and CRO contracted
Nov 30, 2026
PprI constructs generated and sequence verified
Jan 14, 2027
Mammalian cell expression optimized
Mar 04, 2027
DNA damage and repair assays completed
Meet the Team
Affiliates
Isaac Nardi
Isaac K. Nardi, Ph.D. is an Assistant Professor at Arizona College of Nursing in the Department of General Education. He earned his B.S. in Biotechnology from Virginia Tech and Ph.D. in Biochemistry, Molecular Biology, and Genetics from the University of Virginia, where his research focused on chromosome biology, DNA repair, and genome stability.
Over the past decade, Dr. Nardi has led research programs spanning academia, biotechnology startups, and industry, including positions at City of Hope, Beckman Coulter, Kimera Exosomes, Enzymatic LLC, and DemeRx. His work has focused on protein engineering, molecular biology, CRISPR genome engineering, DNA repair, extracellular vesicles, biologics, and translational therapeutics.
He has authored numerous peer-reviewed publications in journals including Current Biology, Molecular Biology of the Cell, Molecular Cancer Research, International Journal of Cancer, Scientific Reports, Journal of Biological Chemistry, and ACS Omega, with his research cited more than 1,400 times. His current research explores whether proteins evolved in extremophiles can uncover new mechanisms to enhance DNA repair and cellular resilience in human cells.
Linkedin: https://www.linkedin.com/in/isaac-k-nardi-9750542a/
Google Scholar: https://scholar.google.com/citations?user=jm4TarwAAAAJ&hl=en
Lab Notes
Nothing posted yet.
Project Backers
- 0Backers
- 0%Funded
- $0Total Donations
- $0Average Donation



